Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Bookworm28on Jun 24, 2021 1:25pm
350 Views
Post# 33444659

Can they bring Otenaproxesul to market?

Can they bring Otenaproxesul to market?I apologize for asking the question, but I've emailed ATE's Investor Relations numerous times over the last year, and they haven't replied. So I'll ask...

Can the company link an H2S molecule onto someone else's NSAID (e.g. Aleve), and sell the resulting product? I know it must sound ridiculous, but like I said, the company isn't replying to my emails. Reading up on patents, and the law appears to state that if the resulting compound does not share any of the original characteristics of the original two compounds, that's acceptable. In the case of Otenaproxesul, you're obviously wanting the pain killing properties of Aleve to persist - No?

I'm no patent expert. I'm just having a hard time with the idea of tagging an H2S molecule onto someone else's NSAID, and calling it your own. I can't imagine Nuance putting up $20MM if this wasn't do-able.

I'd like to buy, and don't mind waiting, but this is a pretty basic question I'd like to get answered before I jump in.

Thanks
<< Previous
Bullboard Posts
Next >>